公开(公告)号：US20200079872A1

公开(公告)日：2020-03-12

申请号：US16548883

申请日：2019-08-23

Applicant: GENMAB A/S

Inventor： Joost J. NEIJSSEN ,  Bart DE GOEIJ ,  Edward Norbert VAN DEN BRINK ,  Aran Frank LABRIJN ,  Rene HOET ,  Janine SCHUURMAN ,  Paul PARREN ,  Jan VAN DE WINKEL

IPC: C07K16/30 ,  C07K16/40 ,  A61K45/06 ,  A61K39/395 ,  C07K16/28 ,  G01N33/574 ,  A61P35/00

Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

公开(公告)号：US20200048304A1

公开(公告)日：2020-02-13

申请号：US16426647

申请日：2019-05-30

Applicant: GENMAB A/S

Inventor： Michael GRAMER ,  Amitava KUNDU ,  Ewald T. J. VAN DEN BREMER ,  Muriel VAN KAMPEN ,  Patrick PRIEM ,  Aran Frank LABRIJN ,  Joyce I. MEESTERS ,  Joost J. NEIJSSEN ,  Janine SCHUURMAN ,  Paul PARREN ,  Patrick VAN BERKEL ,  Werner L. VOS ,  Arnout F. GERRITSEN

IPC: C07K1/113 ,  C07K16/46 ,  C07K16/28

Abstract: The present invention relates to an in vitro method for production of heterodimeric proteins.

公开(公告)号：US20200017600A1

公开(公告)日：2020-01-16

申请号：US16512206

申请日：2019-07-15

Applicant: GENMAB A/S

Inventor： Bart De GOEIJ ,  Grietje ANDRINGA ,  Frank BEURSKENS ,  Janine SCHUURMAN ,  David P.E. SATIJN ,  Tahamtan AHMADI

IPC: C07K16/28 ,  A61P35/00

Abstract: Antibody variants comprising one or more mutations in the Fc region, particularly anti-CD38 antibodies comprising a mutation in one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein the amino acid residues are numbered according to the EU index.

公开(公告)号：US20180215827A1

公开(公告)日：2018-08-02

申请号：US15832337

申请日：2017-12-05

Applicant: GENMAB A/S

Inventor： Bart DE GOEIJ ,  Simone DE HAIJ ,  Thilo RIEDL ,  Rene HOET ,  Ole BAADSGAARD ,  Jan VAN DE WINKEL ,  David SATIJN ,  Paul PARREN ,  Aran Frank LABRIJN ,  Joyce MEESTERS ,  Janine SCHUURMAN ,  Edward N. VAN DEN BRINK

IPC: C07K16/28 ,  C07K16/32

CPC classification number: C07K16/2863 ,  A61K2039/505 ,  C07K16/2809 ,  C07K16/32 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/526 ,  C07K2317/528 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92

Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

公开(公告)号：US20170029521A1

公开(公告)日：2017-02-02

申请号：US15197496

申请日：2016-06-29

Applicant: GENMAB A/S

Inventor： Jan VAN DE WINKEL ,  Tom VINK ,  Janine SCHUURMAN ,  Paul PARREN ,  Rob AALBERSE ,  Marijn VAN DER NEUT KOLFSCHOTEN

IPC: C07K16/28 ,  A61K51/10 ,  A61K47/48

Abstract: The present invention relates to stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370).

Abstract translation: 本发明涉及稳定的IgG4抗体，涉及产生此类抗体的方法以及此类抗体作为药物的用途。 在一个主要方面，本发明涉及一种稳定的IgG4抗体，其包含重链和轻链，其中所述重链包含具有在位置（409）处的Arg残基取代的人IgG4恒定区， 位置（405）或位置（370）处的Lys残基。

公开(公告)号：US20160333095A1

公开(公告)日：2016-11-17

申请号：US15110414

申请日：2015-01-08

Applicant: GENMAB A/S

Inventor： Edward Norbert VAN DEN BRINK ,  Joost J. NEIJSSEN ,  Aran Frank LABRIJN ,  Joyce MEESTERS ,  Janine SCHUURMAN ,  Isil ALTINTAS ,  Paul PARREN ,  Rik RADEMAKER

IPC: C07K16/28 ,  C07K16/42 ,  C07K16/32 ,  G01N33/68

CPC classification number: C07K16/2809 ,  A61K2039/505 ,  C07K16/1063 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/32 ,  C07K16/4241 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/41 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/71 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/90 ,  C07K2317/92 ,  G01N33/6872 ,  G01N2333/7051

Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

Abstract translation: 本发明涉及结合CD3的人源化或嵌合抗体。 此外，它还涉及双特异性抗体，组合物，药物组合物，所述抗体在治疗疾病中的用途，以及治疗方法。

公开(公告)号：US20160168247A1

公开(公告)日：2016-06-16

申请号：US14902757

申请日：2014-07-04

Applicant: GENMAB A/S

Inventor： Edward VAN DEN BRINK ,  Joost J. NEIJSSEN ,  Aran Frank LABRIJN ,  Joyce MEESTERS ,  Janine SCHUURMAN ,  Paul PARREN

IPC: C07K16/28 ,  C07K16/32

Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

公开(公告)号：US20240254252A1

公开(公告)日：2024-08-01

申请号：US17259342

申请日：2019-07-15

Applicant: GENMAB A/S

Inventor： Bart E. C. G. DE GOEIJ ,  Grietje ANDRINGA ,  Frank BEURSKENS ,  Janine SCHUURMAN ,  David SATIJN ,  Tahamtan AHMADI

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/02

CPC classification number: C07K16/2896 ,  A61P35/02 ,  A61K2039/505 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76

Abstract: Antibody variants for therapeutic use involving trogocytosis-mediated reduction of CD38 on CD38-expressing immunosuppressive cells; particularly CD38 antibody variants comprising one or more mutations in the Fc region, such a mutation in one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein the amino 5 acid residues are numbered according to the EU index.

公开(公告)号：US20240150484A1

公开(公告)日：2024-05-09

申请号：US18281372

申请日：2022-03-11

Applicant: GENMAB A/S

Inventor： Bart-Jan DE KREUK ,  Richard HIBBERT ,  Janine SCHUURMAN ,  Aran F. LABRIJN

IPC: C07K16/28 ,  C07K1/107 ,  C07K16/18 ,  C07K16/32

CPC classification number: C07K16/2887 ,  C07K1/1075 ,  C07K16/18 ,  C07K16/2809 ,  C07K16/2833 ,  C07K16/32 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/92 ,  C07K2317/94

Abstract: Described herein are proteins comprising an Fc region or the like, such as monoclonal, bispecific and multispecific antibodies, wherein the Fc region has been modified to eliminate or strongly reduce Fc-mediated effector functions, while at the same time allow for good developability, for therapeutic purposes and where such effector functions are undesired.

公开(公告)号：US20230310599A1

公开(公告)日：2023-10-05

申请号：US18023808

申请日：2021-09-02

Applicant: GENMAB A/S

Inventor： Hreinn BENONISSON ,  Jim MIDDELBURG ,  Thorbald VAN HALL ,  Isil ALTINTAS ,  Kristel KEMPER ,  Janine SCHUURMAN ,  Katy Ann LLOYD ,  Vitalijs OVCINNIKOVS ,  Gijsbertus ZOM

IPC: A61K39/42 ,  A61P35/00 ,  A61P37/04

CPC classification number: A61K39/42 ,  A61P35/00 ,  A61P37/04 ,  A61K2039/545

Abstract: The present invention relates to combination therapy within the field of oncology; in particular to combination therapy with vaccines and binding agents binding to CD3 and to a target antigen on tumor cells.